21 results about "Interferon receptor" patented technology

Provided are: a method for producing an organoid, the method comprising a step for culturing somatic stem cells in a culture medium containing an agonist of the interferon-γ receptor; and a culture medium for producing an organoid, the culture medium containing an agonist of the interferon-γ receptor.

The invention belongs to the technical field of construction methods of disease animal models, and particularly relates to a construction method and application of a renal syndrome hemorrhagic fever mouse model. According to the HTNV infected mouse model established by the method disclosed by the invention, the symptom of the experimental mouse is close to the clinical symptom of a severe hemorrhagic fever with renal syndrome after challenge, the complete lethality and repeatability are high, and the HTNV infected mouse model has the advantages of simple operation, low cost and high efficiency. The method can be used for research on the HTNV pathogenic mechanism and immune mechanism and research and development of antiviral drugs and vaccines, and has great application value for perfecting an HTNV full-chain prevention and control system.

The invention discloses a pig IFNAR2 protein mutant, which is characterized in that the 399th site in the amino acid sequence of the pig IFNAR2 protein is mutated from glycine to alanine, and the amino acid sequence of the pig IFNAR2 protein is as shown in SEQ ID NO. 1. The invention provides a specific cleavage site of ASFV protease pS273R, and the site is mutated through a gene editing technology so as to block the cleavage of pig IFNAR2 by the pS273R and improve the ability of pigs to resist African swine fever virus infection. By blocking ASFV from damaging type I IFN mediated JAK-STAT signal activation, on the basis of retaining pig autoimmune performance, higher specificity and higher efficiency are achieved, negative effects of genetic engineering on pig growth performance and reproductive performance can be greatly reduced, and biosafety is higher.

To provide a new method for treating lupus nephritis (LN), which improves renal response, reduces recurrence, prevents eventual end-stage renal disease (ESRD), and reduces the need for glucocorticoids.SOLUTION: WHAT IS CLAIMED IS: 1. A method of reducing lupus nephritis (LN) disease activity in a subject in need thereof, comprising administering to the subject a type I IFN receptor (IFNAR1) inhibiting agent. Preferably, the IFNAR1 inhibitors are human monoclonal antibodies specific for IFNAR1, such as anifrolumab.SELECTED DRAWING: None

This invention provides an application of type I interferon signaling pathway inhibitors in the preparation of drugs for treating age-related cataracts. By inhibiting type I interferon receptors, it can precisely intervene in the aging mechanism of lens epithelial cells, block the transmission of aging signals, and directly improve lens transparency, exhibiting higher therapeutic efficacy and targeting. The use of IFNAR inhibitors can effectively reverse the aging phenotype caused by STEAP3 deficiency, restore the proliferative capacity of lens epithelial cells, thereby maintaining lens transparency, significantly reducing surgical risks, and providing patients with an early intervention opportunity, delaying the onset and progression of cataracts. IFNAR inhibitors, through precise intervention in specific signaling pathways, have more significant therapeutic effects, and due to their targeting, have fewer side effects and are safer. They can not only improve existing cataracts but also play a preventive and delaying role in the early stages of cataracts. For patients with mild cataracts, the use of type I interferon receptor inhibitors can avoid premature surgical treatment, reducing patient dependence on surgery and also reducing the costs and risks associated with surgery.

The present disclosure provides interferon (IFN) receptor antagonists. The IFN receptor antagonists disclosed herein comprise an anchoring moiety, an IFN masking moiety, an IFN moiety, and a separating moiety, such as a targeting moiety that recognizes an antigen associated with a cell expressing a type 1 interferon receptor and anchors the IFN receptor antagonist to such cell. The disclosure further provides pharmaceutical compositions comprising the IFN receptor antagonists, and methods of using the IFN receptor antagonists in inhibition of IFN signaling, including methods of treatment. Also disclosed are nucleic acids encoding the IFN receptor antagonists, recombinant cells expressing the IFN receptor antagonists, and methods of producing the IFN receptor antagonists.

Provided is a human a interferon receptor binding-related site mutant IFN-α2-EIFK. The mutant has stronger anti-hepatitis B virus activity than IFN-α2, and has no cytotoxic effect at an antiviral concentration. An anti-hepatitis B virus drug can be prepared therefrom.

The invention relates to the field of biological medicine, and relates to application of an interferon receptor 1 monoclonal antibody in preparation of a medicine for treating neuromyelitis optica pedigree diseases and a medicine composition. The antibody regulates immune response by inhibiting abnormal activation of an I-type interferon signal channel and down-regulating interferon stimulation gene expression, so that central nervous system inflammation and demyelination injury are relieved. The humanized IFNAR1 monoclonal antibody is independently used; the compound is combined with a B cell targeting drug to synergistically inhibit B cell activation and antibody secretion; and a bispecific antibody targeting IFNAR1 and a transferrin receptor is constructed, so that the ability of the drug to pass through the blood brain barrier is enhanced, and the concentration of the drug in the brain is improved. In-vivo and in-vitro experiments prove that the treatment scheme can effectively reduce the size of the focus of the NMOSD model and improve the neurological function, and a new precise treatment strategy is provided for AQP4 antibody positive patients.

An antibody selectively activated in a target cell or tissue for treating one of symptoms. The antibody comprises a functional antibody which contains at least one light chain and at least one heavy chain and can be used for treating a condition in an activated state; at least one peptide, which can bind to an interferon receptor as required and activate a signaling pathway of the peptide; and at least one cleavable polypeptide linker, wherein each cleavable polypeptide linker contains a substrate peptide that can be cleaved by means of an enzyme, the enzyme is specifically or highly expressed in a target cell or tissue, and the cleavable polypeptide linker links one of the peptides to the N terminal of one of the at least one light chain and the at least one heavy chain of the functional antibody.

The invention belongs to the technical field of microbial genetic engineering, and discloses a method for detecting binding capacity of poultry interferon and interferon receptor in plants and application thereof, the method comprises the following steps: S1, respectively constructing optimized interferon gene and interferon receptor gene to the N terminal and C terminal of a plant expression vector to obtain a plant expression vector; obtaining a recombinant expression vector; s2, respectively transforming the recombinant expression vectors into agrobacterium host bacteria to obtain genetically engineered bacteria; s3, injecting the genetically engineered bacterium into tobacco, and culturing the tobacco injected with the bacterium liquid, so that the interferon and the interferon receptor are expressed in the tobacco; and S4, capturing a fluorescence signal by using a CCD imaging system, analyzing the fluorescence intensity of a specific region by using image analysis software, and detecting the interaction strength relationship between the interferon protein to be detected and the interferon receptor protein through the fluorescence intensity. The method is convenient to operate, the detection result is visual, the workload can be greatly reduced, and the detection efficiency is improved.

The invention discloses application of an I-type interferon receptor antagonist and / or a signaling pathway inhibitor in preparation of a medicine for preventing and treating heatstroke. Whole genome CRISPR / Cas9 screening finds that an I-type interferon signal channel is significantly activated in cells subjected to heat stress, and qPCR experiments prove that molecules of the I-type interferon signal channel are highly expressed, indicating that the I-type interferon signal channel participates in multi-organ injury after heatstroke. The use of the IFNAR1 neutralizing antibody and / or the I-type interferon signal channel inhibitor can reduce heat stress cell death, and reduce death rate and multi-organ injury of heatstroke mice, which indicates that the IFNAR1 antagonist and / or the I-type interferon signal channel inhibitor can play a role in protecting multiple organs after heatstroke by inhibiting heat stress cell injury and death, and can be used for preventing heatstroke. The clinical development and application prospects are realized.

Provided herein are human interferon alpha-2 (IFNA2) variants that have decreased or no detectable binding to the human interferon-alpha / beta receptor beta 2 (IFNAR2) as compared to the wild-type human IFNA2 polypeptide. Also provided herein are fusion proteins comprising an antibody or fragment thereof, and a human IFNA2 variant, wherein the IFNA2 variant is covalently linked to the antibody, and wherein the IFNA2 variant has decreased or no detectable binding to the human interferon-alpha / beta receptor beta (IFNAR2) as compared to the wild-type human IFNA2 polypeptide.

The invention relates to a construction method of a mouse model for expressing a human III-type interferon receptor gene, and belongs to the technical field of gene engineering. According to the invention, a humanized mouse model is constructed by introducing a human type III interferon receptor gene into a wild mouse. The humanized mouse has good response to the human type III interferon, can better reflect the function of the type III interferon receptor in the human body, provides a more suitable experimental model for researching the signal path of the human type III interferon, and in addition, the humanized mouse can be used for preparing the human type III interferon. The humanized mouse can also be used for evaluating the curative effect and antiviral mechanism of the human type III interferon in treating hepatitis caused by HCV, and can provide a platform for research and development of antiviral and vaccines related to the human type III interferon.

This invention discloses a kit for detecting α-interferon and related applications, relating to the biological field. The kit includes a capture protein for capturing α-interferon and a detection protein for detecting α-interferon; the capture protein includes an α-interferon receptor protein; the detection protein includes an antibody against α-interferon. This kit is applied to IFN-α detection, covering multiple IFN-α subtypes, including natural and recombinant interferon, and exhibits no cross-reactivity with INF-β and INF-ε. It has high detection accuracy and good repeatability, enabling rapid and effective detection of IFN-α levels in human serum, thereby more accurately reflecting the overall level and activity status of IFN-α in the body. This is of great significance for understanding human immune status, diagnosing and monitoring disease development, and evaluating the effectiveness of treatment.

This disclosure provides immune cells (e.g., CAR-T cells) comprising a chimeric antigen receptor and / or an engineered immune cell receptor, that are deficient in interferon y receptor (IFNyR) expression and / or signaling, and methods of use thereof, wherein the CAR-immune cell have increased persistence.

This invention provides a method and unit dose for the treatment of type I IFN-mediated diseases. [Solution] The present invention provides a unit dose for subcutaneous administration of a type I IFN receptor (IFNAR1) inhibitor in a dose greater than 105 mg (>) and less than 150 mg (<), specifically a human monoclonal antibody specific to IFNAR1, or optionally a modified IgG1 class human monoclonal antibody, and a method comprising subcutaneously administering the unit dose to a subject having a type I interferon (IFN)-mediated disease.

The present disclosure provides interferon receptor agonists with improved safety profiles and therapeutic indexes. The interferon receptor agonists are attenuated by masking and / or reduced receptor binding compared to wild-type interferons. The IFN receptor agonists optionally further comprise a targeting moiety, e.g., a targeting moiety that recognizes a tumor-associated antigen or an immune cell-associated antigen and directs the interferon receptor agonist to tumor sites and / or tumor-reactive immune cells. The present disclosure also provides pharmaceutical compositions comprising the interferon receptor agonists and methods of using the interferon receptor agonists in therapy, as well as nucleic acids encoding the interferon receptor agonists, recombinant cells expressing the interferon receptor agonists, and methods of producing the interferon receptor agonists.

An interferon α2b mutant, and a fusion polypeptide and polypeptide construct comprising same. The fusion polypeptide or polypeptide construct comprising the interferon α2b mutant has weakened affinity to an interferon receptor, reduced off-target toxicity, and a tumor killing effect.

The present invention features method and composition that can be used to facilitate intracellular delivery of DNA to a subject. The provided methods and compositions employ a nanoparticle for intracellular DNA delivery and a type 1 interferon receptor pathway inhibitor. The type 1 interferon receptor pathway inhibitor is provided to decrease the subject's immune response that can be stimulated by the DNA.

The present invention relates to a type 1 interferon neutralizing FC-fusion protein and a use thereof and, more specifically, to: a dimer-type polypeptide to which a monomer comprising an interferon receptor fragment or an antibody Fc fragment is bound; a preparation method there for; and a pharmaceutical composition comprising same. The type 1 interferon neutralizing FC-fusion protein of the present invention blocks binding between type 1 interferon and an interferon receptor, and has an excellent ability of inhibiting the signaling and biological activities of interferon, thereby enabling diseases mediated by a type 1 interferon to be effectively treated.

This disclosure relates to methods and compositions for the treatment of SLE. Specifically, this disclosure relates to methods including the administration of type I IFN receptor inhibitors.